Predictive Factors for Poor Outcomes Associated with COVID-19 in a Retrospective Cohort of Myasthenia Gravis Patients
Zhuajin Bi,Huajie Gao,Jing Lin,Mengcui Gui,Yue Li,Zhijun Li,Bitao Bu
DOI: https://doi.org/10.2147/jir.s475729
IF: 4.5
2024-09-01
Journal of Inflammation Research
Abstract:Zhuajin Bi, 1, 2 Huajie Gao, 1, 2 Jing Lin, 1, 2 Mengcui Gui, 1, 2 Yue Li, 1, 2 Zhijun Li, 1, 2 Bitao Bu 1, 2 1 Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, People's Republic of China; 2 Hubei Key Laboratory of Neural Injury and Functional Reconstruction, Huazhong University of Science and Technology, Wuhan, People's Republic of China Correspondence: Zhijun Li, Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, People's Republic of China, Email Bitao Bu, Email Purpose: To investigate the predictors for poor outcomes (including disease exacerbation, hospitalization and myasthenic crisis) in patients with pre-existing myasthenia gravis (MG) following Coronavirus disease 2019 (COVID-19), and to explore the potential effects of COVID-19 on inflammatory and immune responses in MG patients. Patients and Methods: This retrospective cohort study analyzed medical records of 845 MG patients who were diagnosed with COVID-19 between January 2020 to March 2023 at a single medical center. Results: Generalized MG at onset and comorbidities (chronic kidney disease and malignancy) were independent risk factors of poor outcomes. Patients achieving minimal manifestation or better status before COVID-19 had a significantly reduced risk for poor outcomes. Furthermore, patients with older onset age or anti-acetylcholine receptor antibody had a higher risk of exacerbation and hospitalization than those without. Prednisone or immunosuppressant treatment had the potential to reduce the occurrence of poor outcomes, while the duration of prednisone or immunosuppressant usage was associated with a higher risk of poor outcomes. Of the 376 MG patients with blood results available, patients with COVID-19 tended to have higher levels of leukocyte counts, neutrophil-lymphocyte-ratio, hypersensitive C-reactive protein, and Interleukin-6, as well as lower percentages of lymphocytes and regulatory T cells compared to patients without COVID-19. Conclusion: Disease severity at onset, comorbidities, and unsatisfactory control of myasthenic symptoms predicted the occurrence of poor outcomes in MG patients following COVID-19. The risk of poor outcomes was reduced in patients controlled by short-term immunosuppressive therapy. Novel coronavirus might affect inflammatory and immune responses in MG patients, particularly in altering interleukin-6 and regulatory T cell levels. Keywords: myasthenia gravis, COVID‐19, poor outcomes, immunosuppressive treatment, immune responses Myasthenia gravis (MG) is an acquired autoimmune disorder of the neuromuscular junction mediated by pathogenic antibodies targeting acetylcholine receptors (AChR), muscle-specific kinase (MuSK), or lipoprotein-related protein 4 (LRP4). 1,2 Clinically, it is characterized by fluctuating weakness and fatigability of skeletal muscles. The disease course of MG is highly variable, ranging from complete stable remission to relapse and even death. Despite therapeutic advances for the management of MG, approximately 34–69% of patients may experience recurrent exacerbations or even myasthenic crisis (MC) requiring repeated rescue with short-term intravenous immunoglobulin or plasma exchange treatments. 1–3 Importantly, infection (particularly respiratory ones) is thought to be the main contributor to MG exacerbations, accounting for 15–40% of cases and a 3–8% mortality rate. 4–6 Coronavirus Disease 2019 (COVID-19) is a contagious disorder caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. 7–9 It has been reported that patients with MG are more susceptible to COVID-19 due to the weakened immune system and immunosuppressive treatments. 9,10 In addition, several case reports demonstrated that patients with MG might face a particularly severe course of COVID-19 since infections could trigger MG exacerbation and even MC, which imposed a high disease burden on affected patients. 11,12 Currently, although the therapeutic management of MG patients during the COVID-19 pandemic has been guided by expert consensus, predictors for poor outcomes (including disease exacerbation, hospitalization and MC) in MG patients following COVID-19 remain incompletely identified. 13,14 Prognostic factors for poor outcomes can be useful for clinicians to predict which patients are at risk for a more severe and debilitating disease course during the COVID-19 pandemic. Therefore, we conducted a retrospe -Abstract Truncated-
immunology